Paroxysmal Supraventricular Tachycardia (PSVT)
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Milestone PharmaceuticalsQC - Montréal
2 programs1
EtripamilPhase 2
The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MedpaceEtripamil
Milestone PharmaceuticalsThe PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.
Clinical Trials (2)
Total enrollment: 553 patients across 2 trials
Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
Start: Mar 2015Est. completion: Dec 2016199 patients
Phase 2Completed
NCT03353610Milestone PharmaceuticalsThe PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.
The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.
Start: Oct 2017Est. completion: Mar 2020354 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.